Kanamycin-Pos (Kanamycin Monosulphate)

Kanamycin monosulphate binds to the bacterial 30S ribosomal subunit, disrupting the initiation of protein synthesis. This causes misreading of messenger RNA and premature termination of peptide chains, leading to rapid bacterial cell death and clearance of the infection.

The dosing regimen for Kanamycin-Pos is determined by the prescribing clinician based on the type and severity of the infection, patient age, and response to therapy. The prescriber will specify the number of drops, frequency, and duration appropriate for each case.

Safety data for kanamycin monosulphate in pregnancy and lactation are limited. Because systemic absorption from ocular use is possible, the drug should be used only if the potential benefit justifies any potential risk to the fetus or infant, and under medical supervision.

To order Kanamycin-Pos, submit an enquiry on the product page at gnhindia.com, indicating the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Kanamycin-Pos belongs to the aminoglycoside class, offering broad‑spectrum activity against many Gram‑negative ocular pathogens. Compared with other topical aminoglycosides such as tobramycin or gentamicin, kanamycin has a similar spectrum but may differ in potency, resistance patterns, and tolerability, which the prescriber will consider when selecting therapy.

Kanamycin-Pos should be stored at ambient temperature, preferably below 25 °C. Keep the vial in its original packaging, protect it from moisture and direct light, and discard any product that appears cloudy or discolored. Follow standard aseptic techniques when handling the ophthalmic solution.

Kanamycin-Pos is applied as eye drops. The patient should wash their hands, tilt the head back, pull down the lower eyelid, and instill the prescribed number of drops into the conjunctival sac. The eye should be closed gently for a few seconds to allow absorption, and contact lenses should be removed during treatment.

Serious adverse events, although rare, include corneal epithelial toxicity, severe allergic reactions such as anaphylaxis, systemic ototoxicity, and nephrotoxicity if significant systemic absorption occurs. Patients should be instructed to seek immediate medical attention if they experience worsening pain, vision loss, swelling, rash, or hearing changes.

Kanamycin-Pos should be avoided in individuals with a known hypersensitivity to kanamycin, other aminoglycosides, or any component of the formulation. It is also contraindicated for viral, fungal, or allergic eye conditions, and should be used with caution in patients with compromised renal function or those receiving other ototoxic or nephrotoxic drugs.